External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes
Expert Opinion on Pharmacotherapy, cilt.26, sa.10, ss.1237-1243, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 10
- Basım Tarihi: 2025
- Doi Numarası: 10.1080/14656566.2025.2518329
- Dergi Adı: Expert Opinion on Pharmacotherapy
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.1237-1243
- Anahtar Kelimeler: Semaglutide, type 2 diabetes, chronic kidney disease, real-world evidence, survival analysis, observational study, comparative effectiveness
- Boğaziçi Üniversitesi Adresli: Evet
Özet
Background: Clinical trials have shown semaglutide effective in mitigating risks associated with type 2 diabetes and chronic kidney disease. However, semaglutide’s real-world effectiveness and long-term outcomes are not fully established. Research design & methods: Using 2019–2024 Kythera Labs data, an external control arm was created using criteria identified in the FLOW clinical trial. Primary outcomes were major kidney disease events (kidney failure onset and ≥ 50% reduction in estimated glomerular filtration rate from baseline). Propensity score matching and Cox regression were used to determine risk-adjusted outcomes. Results: The control arm (n = 896,257) was compared with the clinical trial cohort (n = 1,766). After propensity score matching on age, sex, socioeconomic status, and comorbidities, semaglutide treatment was associated with a 26% reduction in primary event risk compared with the comparator group (702 vs 1,068 events; HR: 0.74; 95% CI, 0.67–0.81), consistent with the 24% risk reduction observed in the clinical trial. Conclusion: Semaglutide treatment was linked to a significantly lower risk of clinically relevant renal outcomes. Our findings provide robust real-world evidence that supports the FLOW trial results regarding the renoprotective effects of semaglutide, highlighting its promise as an effective therapeutic option for managing renal complications.